Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review.
World J Clin Cases
; 10(27): 9714-9726, 2022 Sep 26.
Article
in English
| MEDLINE | ID: covidwho-2164268
ABSTRACT
BACKGROUND:
Currently, ongoing trials of mesenchymal stem cells (MSC) therapies for coronavirus disease 2019 (COVID-19) have been reported.AIM:
In this study, we investigated whether MSCs have therapeutic efficacy in novel COVID-19 patients.METHODS:
Search terms included stem cell, MSC, umbilical cord blood, novel coronavirus, severe acute respiratory syndrome coronavirus-2 and COVID-19, applied to PubMed, the Cochrane Controlled Trials Register, EMBASE and Web of Science.RESULTS:
A total of 13 eligible clinical trials met our inclusion criteria with a total of 548 patients. The analysis showed no significant decrease in C-reactive protein (CRP) levels after stem cell therapy (P = 0.11). A reduction of D-dimer levels was also not observed in patients after stem cell administration (P = 0.82). Furthermore, interleukin 6 (IL-6) demonstrated no decrease after stem cell therapy (P = 0.45). Finally, we investigated the overall survival (OS) rate after stem cell therapy in COVID-19 patients. There was a significant improvement in OS after stem cell therapy; the OS of enrolled patients who received stem cell therapy was 90.3%, whereas that of the control group was 79.8% (P = 0.02).CONCLUSION:
Overall, our analysis suggests that while MSC therapy for COVID-19 patients does not significantly decrease inflammatory markers such as CRP, D-dimer and IL-6, OS is improved.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Language:
English
Journal:
World J Clin Cases
Year:
2022
Document Type:
Article
Affiliation country:
Wjcc.v10.i27.9714
Similar
MEDLINE
...
LILACS
LIS